In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ARYx Therapeutics, Inc.

http://www.aryx.com/

Latest From ARYx Therapeutics, Inc.

'No Future Without New Drugs': Yuhan CSO On Open Innovation Strategy

Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.

South Korea Innovation

Deal Watch: Organon Obtains Rights To Perjeta, Prolia/Xgeva Biosimilars From Shanghai Henlius

Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.

Deal Watch Business Strategies

Partnerships Picks For GeNeuro’s MS Antibody

The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.

New Science Research & Development

Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?

The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.

South Korea Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register